SELLAS Life Sciences Group, Inc. Lease Obligation Incurred
SELLAS Life Sciences Group, Inc. (SLS) reported Lease Obligation Incurred of -$50.00 thousand for the 126-month period ending 2013-06-30, per its 10-Q filed 2013-08-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2013-08-09
- SELLAS Life Sciences Group, Inc. lease obligation incurred for the quarter ending 2013-06-30 was -$100.00K.
- SELLAS Life Sciences Group, Inc. lease obligation incurred for the quarter ending 2013-03-31 was $0.00.
- SELLAS Life Sciences Group, Inc. lease obligation incurred for the quarter ending 2012-12-31 was $0.00.
- SELLAS Life Sciences Group, Inc. lease obligation incurred for the quarter ending 2012-09-30 was $0.00.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 6 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month | Lease Obligation Incurred 102 month | Lease Obligation Incurred 105 month | Lease Obligation Incurred 108 month | Lease Obligation Incurred 111 month | Lease Obligation Incurred 114 month | Lease Obligation Incurred 117 month | Lease Obligation Incurred 120 month | Lease Obligation Incurred 123 month | Lease Obligation Incurred 126 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013-06-30 | -$100.00K derived: 10-Q 126 month − 10-Q 123 month · filed 2013-08-09 | -$100.00K derived: sum of 2 quarters · filed 2013-08-09 | -$100.00K derived: sum of 3 quarters · filed 2013-08-09 | -$100.00K derived: sum of 4 quarters · filed 2013-08-09 | -$50.00K 10-Q · filed 2013-08-09 | ||||||||
| 2013-03-31 | $0.00 derived: 10-Q 123 month − 10-K 120 month · filed 2013-05-09 | $0.00 derived: sum of 2 quarters · filed 2013-05-09 | $0.00 derived: sum of 3 quarters · filed 2013-05-09 | $0.00 derived: sum of 4 quarters · filed 2013-05-09 | $50.00K 10-Q · filed 2013-05-09 | ||||||||
| 2012-12-31 | $0.00 derived: 10-K 120 month − 10-Q 117 month · filed 2013-03-12 | $0.00 derived: sum of 2 quarters · filed 2013-03-12 | $0.00 derived: sum of 3 quarters · filed 2013-03-12 | $0.00 derived: sum of 4 quarters · filed 2013-03-12 | $50.00K 10-K · filed 2013-03-12 | ||||||||
| 2012-09-30 | $0.00 derived: 10-Q 117 month − 10-Q 114 month · filed 2012-11-13 | $0.00 derived: sum of 2 quarters · filed 2012-11-13 | $0.00 derived: sum of 3 quarters · filed 2012-11-13 | $0.00 derived: sum of 4 quarters · filed 2012-11-13 | $50.00K 10-Q · filed 2012-11-13 | ||||||||
| 2012-06-30 | $0.00 derived: 10-Q 114 month − 10-Q 111 month · filed 2012-08-14 | $0.00 derived: sum of 2 quarters · filed 2012-08-14 | $0.00 derived: sum of 3 quarters · filed 2012-08-14 | $0.00 derived: sum of 4 quarters · filed 2012-08-14 | $50.00K 10-Q · filed 2012-08-14 | ||||||||
| 2012-03-31 | $0.00 derived: 10-Q 111 month − 10-K 108 month · filed 2012-05-14 | $0.00 derived: sum of 2 quarters · filed 2012-05-14 | $0.00 derived: sum of 3 quarters · filed 2012-05-14 | $50.00K 10-Q · filed 2012-05-14 | |||||||||
| 2011-12-31 | $0.00 derived: 10-K 108 month − 10-Q 105 month · filed 2012-03-28 | $0.00 derived: sum of 2 quarters · filed 2012-03-28 | $50.00K 10-K · filed 2012-03-28 | ||||||||||
| 2011-09-30 | $0.00 derived: 10-Q 105 month − 10-Q/A 102 month · filed 2011-11-14 | $50.00K 10-Q · filed 2011-11-14 | |||||||||||
| 2011-06-30 | $50.00K 10-Q/A · filed 2011-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |